logo

Intersect Ent Inc (XENT)



Trade XENT now with
  Date
  Headline
5/11/2020 7:16:50 AM Intersect ENT Q1 Net Loss $17.5 Mln Or $0.54/shr Vs. Net Loss $10.8 Mln Or $0.35/shr Last Year
1/13/2020 7:24:51 AM Intersect ENT Expects Preliminary Unaudited Revenue For Full Year 2019 To Be $109 Mln
11/1/2019 8:35:21 AM Intersect ENT Q3 Total Revenue $24.1 Mln Vs $24.7 Mln Last Year
1/7/2019 8:18:04 AM Intersect ENT Expects Q4 Revenue Of $32.6 Mln To $32.8 Mln, Increase Of 11% From Last Year
12/17/2018 8:23:43 AM Intersect ENT Reports First Patient Enrolled In ASCEND Study Of Investigational Drug-Coated Sinus Balloon
11/5/2018 7:12:47 AM Intersect ENT Q3 Loss/shr Widens To $0.25 From $0.15 Last Year
8/1/2018 8:21:44 AM Intersect ENT Q2 Net Loss Per Share $0.14 Vs Loss $0.08 Last Year
7/17/2018 4:06:48 PM Minerva Neurosciences Elects Jeryl Hilleman To Board Of Directors
5/21/2018 8:09:44 AM SetPoint Medical Appoints Ankit Shah To Lead Commercialization And Marketing
1/8/2018 8:19:43 AM Intersect ENT 2017 Revenue Up 22% Year Over Year
1/7/2018 9:50:22 AM New Drugs Approved In December
11/3/2017 9:19:17 AM Wedbush Is Lowering Intersect ENT Inc (XENT) 2017 Estimate To -0.66 From -0.63
11/3/2017 9:18:54 AM Wedbush Is Raising Intersect ENT Inc (XENT) 2018 Rev. Estimate To 112.7 M From 111.6 M
11/3/2017 9:18:40 AM Wedbush Is Increasing Intersect ENT Inc (XENT) 2017 Rev. Estimate To 94.6 M From 93.5 M
8/2/2017 12:41:31 PM Wedbush Is Lowering Intersect ENT Inc (XENT) 2018 Rev. Estimate To 111.6 M From 112.0 M
8/2/2017 12:41:10 PM Wedbush Is Raising Intersect ENT Inc (XENT) 2017 Rev. Estimate To 93.5 M From 91.1 M
8/2/2017 12:40:36 PM Wedbush Is Increasing Intersect ENT Inc (XENT) Q4 17 Rev. Estimate To 27.8 M From 27.7 M
8/2/2017 12:40:13 PM Wedbush Is Increasing Intersect ENT Inc (XENT) Q3 17 Rev. Estimate To 21.3 M From 20.4 M